ATE214943T1 - Therapeutische zusammensetzungen die monoklonale antikörper enthalten gegen den menschlichen rezeptor für epidermalen wachstumsfaktor - Google Patents

Therapeutische zusammensetzungen die monoklonale antikörper enthalten gegen den menschlichen rezeptor für epidermalen wachstumsfaktor

Info

Publication number
ATE214943T1
ATE214943T1 AT94117268T AT94117268T ATE214943T1 AT E214943 T1 ATE214943 T1 AT E214943T1 AT 94117268 T AT94117268 T AT 94117268T AT 94117268 T AT94117268 T AT 94117268T AT E214943 T1 ATE214943 T1 AT E214943T1
Authority
AT
Austria
Prior art keywords
growth factor
epidermal growth
human epidermal
monoclonal antibodies
compositions containing
Prior art date
Application number
AT94117268T
Other languages
English (en)
Inventor
Francoise Bellot
David Givol
Richard M Kris
Joseph Schlessinger
Original Assignee
Rhone Poulenc Rorer Internat H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26936756&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE214943(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Internat H filed Critical Rhone Poulenc Rorer Internat H
Application granted granted Critical
Publication of ATE214943T1 publication Critical patent/ATE214943T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cephalosporin Compounds (AREA)
  • Supplying Of Containers To The Packaging Station (AREA)
  • Meat, Egg Or Seafood Products (AREA)
AT94117268T 1988-09-15 1989-09-15 Therapeutische zusammensetzungen die monoklonale antikörper enthalten gegen den menschlichen rezeptor für epidermalen wachstumsfaktor ATE214943T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24473788A 1988-09-15 1988-09-15
US31910989A 1989-03-03 1989-03-03

Publications (1)

Publication Number Publication Date
ATE214943T1 true ATE214943T1 (de) 2002-04-15

Family

ID=26936756

Family Applications (2)

Application Number Title Priority Date Filing Date
AT89117125T ATE123070T1 (de) 1988-09-15 1989-09-15 Monoklonale antikörper gegen den rezeptor des epidermis-wachstumsfaktors und diese enthaltende therapeutische zubereitungen.
AT94117268T ATE214943T1 (de) 1988-09-15 1989-09-15 Therapeutische zusammensetzungen die monoklonale antikörper enthalten gegen den menschlichen rezeptor für epidermalen wachstumsfaktor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT89117125T ATE123070T1 (de) 1988-09-15 1989-09-15 Monoklonale antikörper gegen den rezeptor des epidermis-wachstumsfaktors und diese enthaltende therapeutische zubereitungen.

Country Status (10)

Country Link
US (1) US6217866B1 (de)
EP (2) EP0359282B1 (de)
JP (3) JP3600617B2 (de)
AT (2) ATE123070T1 (de)
AU (1) AU4128089A (de)
CA (1) CA1340417C (de)
DE (7) DE122008000030I1 (de)
ES (2) ES2174859T3 (de)
LU (4) LU91116I2 (de)
NL (5) NL300167I1 (de)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US6884418B1 (en) * 1989-08-04 2005-04-26 Berlex Laboratories, Inc. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
WO1992007466A1 (en) * 1990-11-05 1992-05-14 Bristol-Myers Squibb Company Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
CN1314917A (zh) 1998-05-15 2001-09-26 伊姆克罗尼***公司 用辐射和生长因子受体酪氨酸激酶抑制剂治疗人肿瘤
US6824997B1 (en) 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US20080096236A1 (en) * 1998-08-25 2008-04-24 Binax, Inc. Method for Detecting the Presence of Target Bacteria or a Target Component Carbohydrate Antigen Thereof
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
CA2373815A1 (en) * 1999-05-14 2000-11-23 Imclone Systems Incorporated Treatment of refractory human tumors with epidermal growth factor receptor antagonists
TWI269654B (en) 1999-09-28 2007-01-01 Baxter Healthcare Sa N-substituted indole-3-glyoxylamide compounds having anti-tumor action
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
EP1299419A2 (de) * 2000-05-24 2003-04-09 Imclone Systems, Inc. Bispezifische immunglobulinartige antigenbindende proteine und verfahren zur deren herstellung
EP1170011A1 (de) * 2000-07-06 2002-01-09 Boehringer Ingelheim International GmbH Neue Verwendung von Inhibitoren der Rezeptoren des epidermalen Wachstumsfaktors
AU9500201A (en) * 2000-08-09 2002-02-18 Imclone Systems Inc Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
EP1415987B1 (de) * 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) * 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
EP2292251A1 (de) 2001-04-24 2011-03-09 Merck Patent GmbH Kombinationstherapie mit Anti-angiogenen Mitteln und TNF-alpha
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
US7589180B2 (en) * 2001-05-11 2009-09-15 Abbott Laboratories Inc. Specific binding proteins and uses thereof
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
CN100497389C (zh) 2001-06-13 2009-06-10 根马布股份公司 表皮生长因子受体(egfr)的人单克隆抗体
EP1411983A4 (de) * 2001-06-26 2006-06-21 Imclone Systems Inc Bispezifische antikörper, die an vegf-rezeptoren binden
DK1399484T3 (da) * 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
DE10133394A1 (de) * 2001-07-13 2003-01-30 Merck Patent Gmbh Flüssige Formulierung enthaltend Cetuximab
EP1916001B1 (de) 2002-03-04 2011-05-25 Imclone LLC KDR-spezifische menschliche Antikörper und ihre Verwendung
EP1481678A4 (de) * 2002-03-05 2009-12-30 Eisai R&D Man Co Ltd Antitumorales mittel mit einer kombination aus einer sulfonamid-haltigen heterocyclischen verbindung und einem angiogenese-hemmer
KR101086533B1 (ko) 2002-05-24 2011-11-23 쉐링 코포레이션 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
DE60305919T2 (de) * 2002-06-28 2007-01-18 Domantis Limited, Cambridge Dual-specifische liganden mit erhöhter halbwertszeit
HUE025086T2 (en) 2002-10-10 2016-02-29 Merck Patent Gmbh Pharmaceutical preparations for ERB-B1 receptor
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor
TWI229650B (en) * 2002-11-19 2005-03-21 Sharp Kk Substrate accommodating tray
CA2511910A1 (en) * 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US7994159B2 (en) 2003-03-10 2011-08-09 Eisai R&D Management Co., Ltd. c-Kit kinase inhibitor
EP1622941A2 (de) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Methode zur produktion von anti-egfr antikörpern
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
JP2007535895A (ja) 2003-05-01 2007-12-13 イムクローン システムズ インコーポレイティド ヒトインシュリン様成長因子−１受容体に対する完全ヒト抗体
JP2007500248A (ja) 2003-06-09 2007-01-11 ワクサル，サムエル 細胞外アンタゴニストおよび細胞内アンタゴニストによる受容体チロシンキナーゼの抑制方法
BRPI0411803A (pt) 2003-06-27 2006-05-23 Abgenix Inc anticorpos dirigidos aos mutantes de deleção de receptor de fator de crescimento epidérmico e seus usos
EP2251357A1 (de) 2003-11-07 2010-11-17 Ablynx N.V. Camelidae schweren Ketten Antikörpern VHHS gegen Epidermal Growth Faktor Rezeptor (EGFR) und Ihre Verwendungen
JP4303726B2 (ja) * 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
DE10355904A1 (de) 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
US7598350B2 (en) 2004-03-19 2009-10-06 Imclone Llc Human anti-epidermal growth factor receptor antibody
BRPI0509732A (pt) 2004-04-09 2007-09-25 Chugai Pharmaceutical Co Ltd pró-fármaco solúvel em água, composição farmacêutica, agente terapêutico, agente antifungo e uso do referido pró-fármaco
MXPA06014684A (es) * 2004-06-18 2007-02-12 Ambrx Inc Novedosos polipeptidos de enlace antigeno y sus usos.
US8772269B2 (en) * 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
JP4834553B2 (ja) 2004-09-17 2011-12-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
WO2006042313A2 (en) * 2004-10-12 2006-04-20 Imclone Systems Incorporated Egfr antagonist in treatment of fluid accumulation
JP2008519757A (ja) * 2004-11-12 2008-06-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 抗ｅｇｆｒ抗体の固形物
EP1859793B1 (de) * 2005-02-28 2011-04-20 Eisai R&D Management Co., Ltd. Neue kombinierte anwendung einer sulfonamid-verbindung zur behandlung von krebs
EP1879587A2 (de) * 2005-04-15 2008-01-23 Schering Corporation Verfahren und zusammensetzungen zur behandlung oder vorbeugung von krebs
EP1917019A2 (de) * 2005-05-03 2008-05-07 Biopolymer Engineering, Inc. Kombination eines beta-glucans und eines egf-rezeptor-antagonisten zur krebs- und infektionsbehandlung
AU2006259536A1 (en) 2005-06-15 2006-12-28 Schering Corporation Anti-IGF1R antibody formulations
EP2100614B8 (de) 2005-06-17 2013-11-20 ImClone LLC Antikörper gegen PDGFR-alpha zur Verwendung bei der Behandlung von Tumoren
JP2007039346A (ja) * 2005-08-01 2007-02-15 Yokohama Kokusai Bio Kenkyusho:Kk 腫瘍特異的抗体と結合したタキソイド誘導体及びその製造方法
US20100105031A1 (en) * 2005-08-01 2010-04-29 Esai R & D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
WO2007026864A1 (ja) * 2005-09-01 2007-03-08 Eisai R & D Management Co., Ltd. 崩壊性の改善された医薬組成物の製造方法
WO2007042286A1 (en) 2005-10-11 2007-04-19 Merck Patent Gmbh Egfr dependent modulation of chemokine expression and influence on therapy and diagnosis of tumors and side effects thereof
CA2627598C (en) * 2005-11-07 2013-06-25 Eisai R & D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
EP3173084B1 (de) 2005-11-11 2019-10-23 Boehringer Ingelheim International GmbH Chinazolinderivate zur behandlung von krebserkrankungen
EP1948180B1 (de) * 2005-11-11 2013-03-13 Boehringer Ingelheim International GmbH Kombinationsbehandlung gegen krebs mit egfr/her2-hemmern
WO2007061130A1 (ja) * 2005-11-22 2007-05-31 Eisai R & D Management Co., Ltd. 多発性骨髄腫に対する抗腫瘍剤
TW200730539A (en) * 2005-12-01 2007-08-16 Domantis Ltd Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
CN101365486B (zh) 2006-01-04 2012-10-31 默克专利有限公司 使用抗egfr和抗her2抗体的联合治疗
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
EP2015775B1 (de) 2006-05-03 2011-06-01 Bayer Schering Pharma Aktiengesellschaft Kombination aus einem anti-edb-fibronektin-domänen-antikörper l19-sip und einem anti-egfr-antikörper
JP5190361B2 (ja) 2006-05-18 2013-04-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 甲状腺癌に対する抗腫瘍剤
US20090203693A1 (en) * 2006-06-29 2009-08-13 Eisai R & D Management Co., Ltd. Therapeutic agent for liver fibrosis
ES2427924T3 (es) 2006-06-30 2013-11-04 Merck Sharp & Dohme Corp. Biomarcador IGFBP2
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US9090693B2 (en) * 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
AU2008211952B2 (en) 2007-01-29 2012-07-19 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
BRPI0808551B1 (pt) * 2007-03-01 2022-04-05 Symphogen A/S Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende
NZ580530A (en) * 2007-06-06 2012-04-27 Domantis Ltd Anti vegf polypeptides, antibody variable domains and antagonists
KR100883430B1 (ko) * 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
WO2008154927A1 (en) * 2007-06-21 2008-12-24 Genmab A/S Novel methods for treating egfr-associated tumors
JP5532486B2 (ja) * 2007-08-14 2014-06-25 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｅｇｆ受容体を標的とするモノクローナル抗体１７５ならびにその誘導体および用途
EP3492488A1 (de) 2007-08-22 2019-06-05 The Regents of The University of California Aktivierbare bindende polypeptide und verfahren zu deren identifikation und anwendung
AU2008307643B9 (en) 2007-09-28 2014-04-17 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
US8216571B2 (en) * 2007-10-22 2012-07-10 Schering Corporation Fully human anti-VEGF antibodies and methods of using
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
KR101506062B1 (ko) * 2008-01-29 2015-03-25 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 저해 물질과 탁산의 병용
HUE034465T2 (en) * 2008-02-11 2018-02-28 Cure Tech Ltd Monoclonal antibodies for tumor treatment
AR070861A1 (es) * 2008-03-06 2010-05-12 Genentech Inc Uso de terapia de combinacion con antagonistas de c-met y egfr
AR071891A1 (es) * 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
BRPI0918768B1 (pt) 2008-08-29 2022-08-30 Symphogen A/S Composições de anticorpo recombinante de antireceptor do fator de crescimento epidérmico
WO2010028288A2 (en) 2008-09-05 2010-03-11 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
EP3543256A1 (de) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modifizierte antikörperzusammensetzungen, verfahren zur herstellung und verwendung davon
CA2753294A1 (en) 2009-02-23 2010-08-26 Cytomx Therapeutics, Inc. Proproteins and methods of use thereof
CN104447995A (zh) * 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 双特异性抗-her抗体
EP2451445B1 (de) 2009-07-06 2019-04-03 Boehringer Ingelheim International GmbH Verfahren zur trocknung von bibw2992, seiner salze und fester pharmazeutischer formulierungen mit diesem wirkstoff
US20120288495A1 (en) 2009-07-22 2012-11-15 Biothera, Inc. Therapeutic compositions and methods
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
MX2012004780A (es) 2009-10-23 2012-08-23 Lilly Co Eli Inhibidores de akt.
EP2542692B1 (de) 2010-03-04 2016-08-24 Carpén, Olli Verfahren zur auswahl von patienten zur behandlung mit einem egfr-hemmer
EP2371369A1 (de) 2010-04-01 2011-10-05 Institut Gustave Roussy (IGR) EGFR-Inhibitor und antivirales Mittel zur gleichzeitigen, getrennten oder aufeinanderfolgenden Verwendung bei der Behandlung und/oder Vorbeugung und/oder Abschwächung von Krebs
WO2011156617A2 (en) 2010-06-09 2011-12-15 Aveo Pharmaceuticals, Inc. Anti-egfr antibodies
CA2802644C (en) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
US9464136B2 (en) 2010-08-20 2016-10-11 Massachusetts Institute Of Technology Antibody-based constructs directed against tyrosine kinase receptors
MX346956B (es) 2010-09-24 2017-04-06 Univ Leland Stanford Junior Captura directa, amplificación y secuenciación de objetivo adn usando cebadores inmovilizados.
JP6243737B2 (ja) 2010-10-27 2017-12-06 ザ リサーチ ファウンデーション フォー ザ ステイト ユニバーシティ オブ ニューヨーク Ｅ−カドヘリンの可溶性細胞外ドメインを標的とする組成物および癌治療のための関連方法
CN105399831A (zh) 2010-10-29 2016-03-16 伊缪诺金公司 非拮抗性egfr结合分子及其免疫偶联物
EP2632490A4 (de) 2010-10-29 2014-10-22 Immunogen Inc Neue egfr-bindende moleküle und immunkonjugate davon
EP2640384A1 (de) 2010-11-18 2013-09-25 Synta Pharmaceuticals Corp. Vorauswahl von personen für eine therapeutische behandlung mit sauerstoffempfindlichen mitteln auf der basis des hypoxischen status
CA2831957A1 (en) 2011-04-07 2012-10-11 Amgen Inc. Novel egfr binding proteins
CA2828946C (en) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
KR102096224B1 (ko) 2011-10-28 2020-04-03 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 폴리펩티드 구축물 및 이의 용도
EP2794010A4 (de) 2011-11-21 2015-10-21 Immunogen Inc Verfahren zur behandlung von gegen egfr-therapien resistenten tumoren durch ein egfr-antikörper-zytotoxikum-konjugat
JP6324381B2 (ja) 2012-07-31 2018-05-16 クラウン バイオサイエンス インコーポレイテッド（タイカン） 抗ｅｇｆｒ薬物による処置のための非小細胞肺癌患者を同定するための組織学的マーカー
SI2882440T1 (sl) 2012-08-07 2019-05-31 Novartis Ag Farmacevtske kombinacije, ki vsebujejo inhibitor B-RAF, inhibitor EGFR in neobvezno inhibitor PI3K-alfa
PL2766048T3 (pl) 2012-10-12 2015-05-29 Medimmune Ltd Pirolobenzodiazepiny i ich koniugaty
WO2014098176A1 (ja) 2012-12-21 2014-06-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
KR102228358B1 (ko) 2012-12-21 2021-03-16 쉬케후세트 솔란데트 에이치에프 신경 장애 및 통증의 ｅｇｆｒ 표적 치료
AR094778A1 (es) 2013-02-13 2015-08-26 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteínas con glicosilación modificada y métodos para producirlas
KR20160002713A (ko) 2013-02-13 2016-01-08 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 고도로 갈락토실화된 항-tnf-알파 항체 및 이의 용도
US20160031887A1 (en) 2013-03-13 2016-02-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
NZ713641A (en) 2013-04-29 2019-08-30 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
US9914770B2 (en) * 2013-04-30 2018-03-13 Intas Pharmaceuticals Ltd Cloning, expression and purification method for the preparation of ranibizumab
KR102204279B1 (ko) 2013-05-14 2021-01-15 에자이 알앤드디 매니지먼트 가부시키가이샤 자궁내막암 대상의 렌바티닙 화합물에 대한 반응성을 예측 및 평가하기 위한 생체표지
CN110496099B (zh) 2013-09-11 2022-06-21 伊戈尔生物药品股份有限公司 包含粘度降低剂的液体蛋白质制剂
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
MX2017001980A (es) 2014-08-28 2017-05-04 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y metodo para su produccion.
EP3193940A1 (de) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepine und konjugate daraus
MX2017004306A (es) 2014-10-01 2017-12-20 Eagle Biologics Inc Formulaciones de polisacáridos y ácido nucleico que contienen agentes de reducción de viscosidad.
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
CA2965862A1 (en) 2014-10-28 2016-05-06 Merck Patent Gmbh Methods for non-covalent fc-domain-containing protein display on the surface of cells and methods of screening thereof
US10544199B2 (en) 2014-10-29 2020-01-28 Teva Pharmaceuticals Australia Pty Ltd Interferon alpha 2B variants
HUE058851T2 (hu) 2014-12-05 2022-09-28 Xyphos Biosciences Inc Inzertálható variábilis antitestfragmentumok és az NKG2D ligandumok módosított A1-A2 doménjei
BR112017017428A2 (pt) 2015-02-25 2018-04-03 Eisai R&D Management Co., Ltd. ?método para supressão do amargor de derivado de quinolina?
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
JP6757959B2 (ja) 2015-06-16 2020-09-23 株式会社 ＰＲＩＳＭ ＢｉｏＬａｂ 抗がん剤
CN105237638A (zh) * 2015-10-26 2016-01-13 无锡傲锐东源生物科技有限公司 抗egfr蛋白单克隆抗体杂交瘤细胞及其产生的抗egfr单克隆抗体和应用
WO2017186950A1 (en) 2016-04-28 2017-11-02 Biomunex Pharmaceuticals Bispecific antibodies targeting egfr and her2
SG11201810793XA (en) 2016-06-03 2018-12-28 Giordano Caponigro Pharmaceutical combinations
CA3027908A1 (en) 2016-06-24 2017-12-28 Xyphos Biosciences Inc. Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
CN106800599B (zh) * 2016-12-05 2021-03-23 中国人民解放军第二军医大学 抗人EGFR和Notch多特异性抗体、其制备方法及用途
ES2971448T3 (es) 2017-02-08 2024-06-05 Eisai R&D Man Co Ltd Composición farmacéutica para el tratamiento de tumores
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
US11123330B2 (en) 2017-09-28 2021-09-21 The Governing Council Of The University Of Toronto Methods and compositions for inhibiting mutant EGFR signaling
CN113286616A (zh) 2018-05-23 2021-08-20 Adc治疗有限公司 分子佐剂
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
CN113573728A (zh) * 2018-11-14 2021-10-29 安驰肿瘤公司 治疗性SIRPα抗体
US11279698B2 (en) 2018-11-20 2022-03-22 Cornell University Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
EP3947440A1 (de) 2019-03-29 2022-02-09 F. Hoffmann-La Roche AG Verfahren zur erzeugung von avid-bindenden multispezifischen antikörpern
US20220211847A1 (en) 2019-05-06 2022-07-07 Medimmune Limited Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatment of colorectal cancer
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
US20240207463A1 (en) 2021-03-31 2024-06-27 Nihon Medi-Physics Co., Ltd. Radioactive complex of anti-egfr antibody, and radiopharmaceutical
WO2022262879A1 (es) 2021-06-14 2022-12-22 Centro De Inmunología Molecular Uso de anticuerpos monoclonales contra el receptor del factor de crecimiento epidérmico en el tratamiento de pacientes con insuficiencia respiratoria aguda hipoxémica
CN117980326A (zh) 2021-07-14 2024-05-03 2赛文缇生物公司 与来自抗体的结合结构域融合的经工程化的t细胞受体
WO2023166098A1 (en) 2022-03-02 2023-09-07 Biomunex Pharmaceuticals Bispecific antibodies binding to her-3 and to either her-2 or egfr
WO2023196997A2 (en) 2022-04-08 2023-10-12 2Seventy Bio, Inc. Multipartite receptor and signaling complexes
WO2024121226A1 (en) 2022-12-07 2024-06-13 Hummingbird Bioscience Pte. Ltd. Combination for treatment and prevention of cancer
WO2024126660A1 (en) 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Combination therapy for cancer treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法

Also Published As

Publication number Publication date
DE122008000028I1 (de) 2008-09-18
EP0667165B1 (de) 2002-03-27
US6217866B1 (en) 2001-04-17
EP0667165A1 (de) 1995-08-16
DE122008000030I1 (de) 2008-09-18
JP2005047934A (ja) 2005-02-24
JP3600617B2 (ja) 2004-12-15
JP3732426B2 (ja) 2006-01-05
EP0359282A2 (de) 1990-03-21
JP2002114710A (ja) 2002-04-16
ATE123070T1 (de) 1995-06-15
EP0359282A3 (en) 1990-05-23
NL300350I1 (nl) 2008-08-01
ES2075019T3 (es) 1995-10-01
LU91116I2 (en) 2004-12-29
JP4122393B2 (ja) 2008-07-23
DE122008000027I1 (de) 2009-01-29
DE122004000041I1 (de) 2005-02-24
NL300353I1 (nl) 2008-08-01
DE122004000040I1 (de) 2005-02-24
NL300351I1 (nl) 2008-08-01
LU91449I2 (fr) 2008-07-29
NL300167I1 (nl) 2005-03-01
ES2174859T3 (es) 2002-11-16
JPH02291295A (ja) 1990-12-03
CA1340417C (en) 1999-03-02
DE68929384D1 (de) 2002-05-02
LU91117I2 (en) 2004-12-29
AU4128089A (en) 1990-03-22
EP0359282B1 (de) 1995-05-24
LU91448I2 (fr) 2008-07-29
DE68929384T2 (de) 2002-11-21
DE68922808T2 (de) 1995-09-21
DE68922808D1 (de) 1995-06-29
NL300166I1 (nl) 2005-03-01

Similar Documents

Publication Publication Date Title
ATE214943T1 (de) Therapeutische zusammensetzungen die monoklonale antikörper enthalten gegen den menschlichen rezeptor für epidermalen wachstumsfaktor
ES2154354T3 (es) Ligandos tie-2, metodos para obtenerlos y sus usos.
NO982062L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
DK0403156T3 (da) Forbedrede monoklonale antistoffer mod den humane alfa/beta-T-cellereceptor samt fremstilling og anvendelse deraf
ATE106750T1 (de) Funktionspezifische antikörper.
ES2102196T3 (es) Periferializacion de celulas pluripotenciales hematopoyeticas.
HU9202073D0 (en) Antibody-antagonists of human interleucin-4
ATE252637T1 (de) Antikörper gegen lymphozyten-assoziiertes zelloberflächenprotein
TW272197B (de)
DE3586194D1 (de) Bioemulgatoren enthaltende kosmetische und pharmazeutische zusammensetzungen.
IT8967049A0 (it) Anticorpo umano monoclonale composizione terapeutica che lo contiene linea cellulare capace di produrre l anticorpo procedimento per la suaproduzione
IT8946502A0 (it) Metodologia dell'accrescimento del pene